Kinase Inhibitor Selectivity

Kinase inhibitor selectivity determines pharmaceutical engagement specificity across diverse kinase families. Broad-spectrum inhibitors block multiple kinases causing off-target toxicity. Selective inhibitors restrict activity to intended targets improving tolerability. Structure-based design achieves selectivity through steric constraints. Biochemical screening validates selectivity across kinase panels.

Off-target kinase inhibition produces unexpected adverse effects. Selectivity window defines safe therapeutic concentrations. Resistance mechanisms from kinase mutations warrant monitoring. Regulatory submissions justify selectivity rationale. Post-approval monitoring identifies unexpected selectivity patterns.